Coiled Therapeutics plc (FRA:0AG0)

Market Cap	33.24M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,000
Open	0.0524
Previous Close	0.0579
Day's Range	0.0524 - 0.0581
52-Week Range	0.0010 - 0.2100
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	May 6, 2027

About Coiled Therapeutics

Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company’s lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical...

• Industry: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices
• CEO: Sridhar Vempati
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0AG0

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 13, 2026

Data Sources Report a data error